TCR-dependent sensitization of human γδ T cells to non-myeloid IL-18 in cytomegalovirus and tumor stress surveillance

Florent Guerville1,2,3, Sophie Daburon1,2,8, Romain Marlin1,2, Lydia Lartigue4,
Severine Loizon1,2, Vincent Pitard1,2, Lionel Couzil1,2,3, Jean-François Moreau1,2,5,
Julie Déchanet-Merville1,2,8, and Benjamin Faustin1,2,8

1Bordeaux University; CIRID; Bordeaux, France; 2CNRS, UMR 5164, Bordeaux, France; 3Nephrology and Renal Transplantation Department; Bordeaux University Hospital; Bordeaux, France; 4INSERM U916 VINCO, Institut Bergonié, Bordeaux, France; 5Immunology and Immunogenetics Laboratory, Bordeaux University Hospital, Bordeaux, France

*These authors contributed equally to this work.

Keywords: cancer, cytomegalovirus, caspase-1, γδ T cells, IL-18, immunology, inflammasome, TCR

Human γδ T cells contribute to tissue homeostasis under normal conditions and participate in lymphoid stress surveillance against infection and tumors. However, the molecular mechanisms underlying the recognition of complex cell stress signatures by γδ T cells are still unclear. Tumor cells and human cytomegalovirus (HCMV)-infected cells are known targets of γδ T cells. We show here that many tumor and CMV-infected cells express caspase-1 inflammasomes and release interleukin (IL)-18. Engagement of the T-cell receptor (TCR) on Vδ2neg γδ T cells controlled the direct innate immune sensing of IL-18 that enhanced cytotoxicity and interferon gamma (IFNγ) production. This TCR-dependent sensitization to IL-18 was mediated by the upregulation of the innate IL-18 receptor β chain (IL-18Rβ) expression. These findings shed light on inflammasomes as a unified stress signal of tumor and infected cells to alert γδ T cells. Moreover, uncovering the TCR-mediated sensitization of γδ T cells to inflammatory mediators establishes a molecular link between the innate and adaptive immune functions of γδ T cells that could fine tune the commitment of antigen-experienced γδ T cells to inflammatory responses.

Introduction

The presence of γδ T cells, along with αβ T cells and B cells, in all higher vertebrates suggest that each contributes uniquely to host immune competence and is essential for its maintenance. Human γδ T cells are a relatively rare immune population in peripheral blood, mostly composed of cells expressing the Vγ9Vδ2 variable regions. Epithelial tissues are substantially enriched in other γδ T-cell subsets (collectively called Vδ2neg γδ T cells) that mediate first-line host response to a wide variety of cellular insults triggered by malignancy or bacterial/viral infection, and contribute to tissue homeostasis.1,2 The γδ T cells have been shown to recognize stress-associated proteins, metabolites, and lipids in a classical major histocompatibility complex (MHC)-unrestricted manner.3 A critical protective role against tumors and infections has been demonstrated in vivo using γδ T-cell-deficient mice 3,4 as well as in the context of chemotherapy.3 Human γδ T cells can infiltrate tumors and infected tissues, and their expansion in blood correlates with better clinical outcome in both malignancies and infectious diseases.6,7 Notably, they can also regulate αβ T cells 8,9 and maintain tissue integrity.10 In vitro, human γδ T cells can kill transformed cells, infected cells, and microorganisms. To date, phase 1 and 2 clinical trials have been conducted to evaluate the use and efficacy of Vγ9Vδ2 γδ T-cell-based immunotherapy. Trials against solid tumors revealed mixed results, as they were hampered by fluctuating responses to ex vivo stimulation and a strong susceptibility of this population for activation-induced cell death (AICD).11

Interestingly, AICD seems to be reduced for epithelial Vδ2neg γδ T cells, and increasing evidence supports an important role of this subset for tumor and infection immunosurveillance.12 Human Vδ2neg γδ T cells expand in the periphery of individuals during CMV infection in various pathophysiological contexts, including solid-organ and stem cell transplantation,13–17 where they develop cytotoxic function and produce proinflammatory cytokines such as tumor necrosis factor α (TNFα) and IFNγ.18 Importantly, CMV-induced expansion of Vδ2neg γδ T cells correlates with decreased susceptibility to post-transplant cancers.
suggesting a role in tumor immunosurveillance in vivo. In line with this, such cells display a TCR-dependent cross-reactivity to several solid tumor cell lines and CMV-infected cells, which can be explained by the recognition of common, specific, stress-induced γδ TCR ligands (e.g., EPCR) expressed by cellular targets in both conditions. However, a complex array of co-stimulatory signals along with TCR engagement seem to be required to fine tune appropriate Vδ2neg γδ T-cell responses to tissue stress.

Inflammasomes are multi-protein complexes that stimulate caspase-1, and initiate inflammatory signaling in response to molecular determinants produced by pathogens and cell stress. Two types of inflammasomes have been described, involving either nucleotide-binding domain leucine-rich repeat-containing receptors (NOD-like receptor [NLRs] family proteins) or the PYHIN family protein (absent in melanoma 2 [AIM2]-like receptors). These serve as anchoring scaffolds onto which protein-complex assembly occurs to process pro-caspase-1 into active caspase-1. Subsequently, active caspase-1, composed of the hetero-tetramer (p10)2/(p20)2, facilitates maturation of pro–IL-1β and pro–IL-18 into active cytokines to be secreted and prime the inflammatory response. While playing critical roles in host defense against pathogens, NLR functions have also been associated with the progression of metabolic syndrome, thereby contributing to their definition as danger sensors of metabolic stress. Two types of inflammasomes have been described, involving either nucleotide-binding domain leucine-rich repeat-containing receptors (NOD-like receptor [NLRs] family proteins) or the PYHIN family protein (absent in melanoma 2 [AIM2]-like receptors). These serve as anchoring scaffolds onto which protein-complex assembly occurs to process pro-caspase-1 into active caspase-1. Subsequently, active caspase-1, composed of the hetero-tetramer (p10)2/(p20)2, facilitates maturation of pro–IL-1β and pro–IL-18 into active cytokines to be secreted and prime the inflammatory response. While playing critical roles in host defense against pathogens, NLR functions have also been associated with the progression of metabolic syndrome, thereby contributing to their definition as danger sensors of metabolic stress. Interestingly, inflammasome assembly seems to occur in response to a metabolic reprogramming similar to the one triggered by both cellular transformation and viral infection (including CMV). IL-18 is crucially involved in tissue homeostasis. In vivo studies have shown IL-18 expression during late stages of tumorigenesis in tumor tissues and the serum of patients with various types of cancer together with an immunoblativle role of natural killer (NK) cells. Various epithelial cells express NLRs; however, the role of NLRs in the activation of inflammasomes within tissue-derived malignant and infected cells, as well as their direct role in controlling effector functions of intraepithelial lymphocytes (IEL), remains to be defined. We hypothesized that inflammasome activation may represent a unified stress signal triggered by both CMV infection and cellular transformation, which in turn could modulate human Vδ2neg γδ T-cell response through the secretion of soluble signaling molecules including IL-1β and IL-18 cytokines. Such a mechanism may represent an additional stress signal recognized by γδ T cells to sense disturbed tissue integrity.

Results

Tissue-derived cellular targets of human Vδ2neg γδ T cells secrete mature IL-18

Human Vδ2neg γδ T cells recognize a wide range of cancer cells as well as CMV-infected endothelial cells through a γδ–TCR-dependent mechanism. We first evaluated whether these cancer cells may secrete inflammasome-dependent inflammatory cytokines including IL-1β and IL-18, as well as products of antigen-presenting cells (APCs) such as IL-12. We screened several human cancer cell lines and noticed the secretion of mature IL-18, from glioblastoma U373MG and U343MG, lung adenocarcinoma SKMES-1, and hepatocarcinoma HUH7, as measured by ELISA (ranging from 50 to 200 pg/mL) (Fig. 1A). In contrast to IL-18, mature IL-1β and IL-12 were not detected from the supernatants of tested cell lines (except minor amounts of IL-12 for HT1080), although both were readily detectable in culture supernatants of the lipopolysaccharide (LPS)/adenosine triphosphate (ATP)-activated monocytic THP-1 cell line used as a positive control (Fig. 1B). We also observed a significant increase of IL-18 secretion from human umbilical vein endothelial cells (HUVECs) following HCMV infection with increased doses of virus (Fig. 1C). Secretion of mature IL-1β followed that of IL-18 but to a lesser extent, and IL-12 secretion was barely detected from HCMV-infected HUVEC cultures (Fig. 1D). Therefore, both human targets of Vδ2neg γδ T cells tested here (cancer cells and HCMV-infected cells) secrete caspase-1-dependent cytokines.

γδ TCR signaling sensitizes Vδ2neg γδ T cells to soluble IL-18, thereby enhancing IFNγ production

To address whether non-myeloid IL-18 could participate in γδ T-cell activation by tumor and CMV-infected cells, it was first important to assess the γδ T-cell response to recombinant IL-18. Therefore, we investigated the direct effect of IL-18 ex vivo on fresh peripheral blood mononuclear cells (PBMCs) isolated from CMV-infected kidney transplant recipients that contained at least 15% of Vδ2neg γδ T cells (mostly expressing Vδ1 and Vδ3) among CD3+ T cells (Fig. 1E; Fig. S1). Among PBMCs, the Vδ2neg γδ T cells were specifically stimulated through the TCR (by using anti-Vδ1+ anti-Vδ3 Abs), and left untreated or treated with IL-18 or IL-1β. IL-18, but not IL-1β, strongly induced IFNγ secretion from bulk PBMCs, but only in the presence of TCR stimulation mediated by both anti-Vδ1 and anti-Vδ3 Abs used either combined (Fig. 1F) or separately (Fig. 1G). Among PBMCs from 7 patients that were tested, none showed an increase of IFNγ secretion after IL-18 treatment alone, conversely to that with co-treatment with IL-18 and γδ TCR agonists (Fig. 1H). Normalized by the level of IFNγ secreted in the presence of TCR agonists, 4 patients showed a >fold4 increase of IFNγ secretion upon IL-18 stimulation versus no IL-18 (Fig. 1I). Therefore, IL-18 treatment of patient PBMCs acts synergistically with TCR stimulation to enhance IFNγ secretion.

As IL-18-mediated IFNγ secretion from PBMCs might be attributed to indirect effects on other cells among PBMCs (αβ T and NK cells), we investigated whether purified Vδ2neg γδ T cell clones and short-term polyclonal cell lines would behave similarly. We used purified Vδ2neg γδ T-cell clones (expressing Vγ4Vδ5, Vγ8Vδ3, or Vγ2Vδ3 TCRs) and short-term polyclonal cell lines (Vδ1, Vδ1+ Vδ3, and Vδ5) generated from the blood of CMV-infected patients as described in Halary et al. First, γδ T cells were stimulated with increased concentrations of anti-CD3 in the presence or absence of recombinant cytokines IL-18 or IL-1β (Fig. 2A and B). For all clones tested, the amount of IFNγ secreted was significantly higher in the presence of IL-18, regardless
**Figure 1.** IL-18 is secreted by cancer cells and HCMV-infected cells, and enhances IFNγ production by human Vd2neggd T cells within PBMCs. (A) IL-18 or (B) IL-1β and IL-12 secretion by cancer cell lines. Cancer cell lines were cultured for 48 h and the secretion of cytokines was measured by ELISA from cell culture supernatants. Results are normalized by the same amount of cells used for each cell line. HUVEC endothelial cells were infected with HCMV at various multiplicities of infection (MOIs), and cell culture supernatant at 24 and 48 h post-infection was used to monitor (C) IL-18 or (D) IL-1β and IL-12 secretion by ELISA. Data are expressed as concentration of cytokines (pg/mL; mean ± SD; n = 3). (E) Example of Panδ immunotyping from whole blood. Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of a kidney transplant patient and Panδ populations were quantified using anti-panδ and anti-Vδ2 antibodies within the CD3+ population by flow cytometry. (F) PBMCs isolated from a patient with expanded Vδ2neg population (>12% of CD3+) were incubated with various concentrations of anti-Vδ1 and anti-Vδ3 antibodies in the presence or absence of recombinant IL-18 (50 ng/mL) for 24 h at 37°C, then IFNγ secretion was measured by ELISA from cell culture supernatants (mean ± SD; n = 3). (G) Same as in (F) but PBMCs from another patient were treated with either anti-Vδ1 or anti-Vδ3 antibodies at various concentrations in the presence or absence of recombinant IL-18 or IL-1β (50 ng/mL) for 24 h at 37°C; then, IFNγ secretion was measured by ELISA from cell culture supernatants (mean ± SD; n = 3). (H) IFNγ secretion obtained from several kidney transplant patient’s PBMCs was normalized by the same number of Vδ2neggd T cells and plotted as raw data. Anti-Vδ indicates treatment with combined anti-Vδ1-anti-Vδ3 antibodies (10 μg/mL each). (I) IL-18 response is represented as fold induction of IFNγ secretion after IL-18 treatment (anti-Vδ2neggδ+IL-18/anti-Vδ2neggδ), *p < 0.05.
of IL-1β. These results were confirmed on short-term polyclonal cell lines (Vβ1, Vβ1+ Vβ3, and Vβ5) activated with either anti-Vβ1 monoclonal antibody (mAb) or anti-CD3 (Fig. 2C–E). TNFα secretion was also measured, with the same result as for IFNγ secretion (Fig. S2A). The effects of IL-18 were not restricted to Vβ2neg γδ T cells because they
were also observed on purified and expanded polyclonal Vγ9Vβ2 T cells isolated from 2 different healthy donors, upon TCR stimulation using anti-Vβ2 antibody (Ab) (Fig. 2F). Therefore, TCR-stimulated γδ T cells respond directly to IL-18 and likely contribute to the IFNγ production observed in PBMCs.

We next tested whether IL-18 could synergize with others cytokines to increase IFNγ production. IFNγ secretion was measured in the presence of cytokines alone (IL-1β, IL-18, IL-12, and IL-15) or in combination. When used alone, only IL-12 or IL-18 increased IFNγ secretion following anti-CD3 treatment (using either Vβ1 or Vβ5 polyclonal cell lines; Fig. 2G; Fig. S2B, respectively). The combination of IL-18 and IL-12 had a synergistic effect even in the absence of TCR stimulation (as already observed for αβ T cells).36 The TCR-mediated effect on the IL-18 response could not be attributed to IL-12 secretion by γδ T cells themselves because anti-CD3 treatment of Vβ1 polyclonal cell line did not induce any detectable IL-12 in cell culture supernatant (neither IL-18), while inducing IFNγ (Fig. 2H). In conclusion, the TCR-dependent response to IL-18 is a general mechanism among all human Vδ2β2+ γδ T cells tested (clones and polyclonal cell lines) that mediates at least a fold2-induction of IFNγ secretion in comparison to TCR signaling alone (Fig. 2I). Vδ2β2+ γδ T cells do not require any other co-factor provided by APCs such as IL-12 to respond to IL-18, although this combination can lead to a better response. Strikingly, the γδ T-cell responsiveness to IL-18 is highly dependent on the strength of γδ TCR signaling.

γδ TCR signaling induces the expression of IL-18Rβ chain

We next tested whether γδ TCR engagement would increase IL-18 sensing by upregulating expression of the cell membrane receptor IL-18Rβ (which controls the number of high-affinity IL-18 receptors).37 This was tested on various Vδ2β2+ γδ T cells (clones and polyclonal cell lines), upon γδ TCR stimulation by anti-CD3 agonist Ab. We detected basal expression of IL-18Rβ in approximately 10% of γδ T-cell clones (Vγ9Vβ1) and polyclonal cell lines (Vβ1, Vβ1+3, Vβ5) (Fig. 3A). Upon anti-CD3 stimulation, we noticed a dose-dependent increase of the number of IL-18Rβ-positive cells by at least fold2-(Fig. 3B). These results suggest 1 a molecular link between γδ TCR signaling and the expression of innate IL-18Rβ, and 2 that TCR-mediated responses to IL-18 might be a specific characteristic of γδ T cells that allows them to enhance IFNγ production and cytotoxicity.

Soluble IL-18 secreted from tumor and infected target cells enhances IFNγ production by Vδ2β2+ γδ T cells

Cancer cells and HCMV-infected endothelial cells are both targets of Vδ2β2+ γδ T cells, and both can secrete IL-18. Therefore, we tested if conditioned culture supernatant of target cells can promote IFNγ secretion from Vδ2neg γδ T cells in the presence of TCR signaling. Polyclonal Vδ2β2+ γδ T-cell lines were incubated with plate-coated anti-CD3 and the conditioned culture supernatants (CS) of either cancer cells or HCMV-infected HUVEC cells. We first screened various CS with the Vδ1 polyclonal cell line and observed that glioblastoma U373MG, lung adenocarcinoma SKMES-1, and hepatocarcinoma HUH7 were potently able to enhance IFNγ secretion, which is consistent with the level of IL-18 secreted by these cells (Fig. 1A). At least a fold4 increase was observed at 1 μg/mL of anti-CD3 stimulation (Fig. 4A). γδ T-cell responsiveness to CS followed the amounts of U373MG cancer cells used to generate the CS as shown in Figure 4B. Importantly, no effect of CS was observed without TCR stimulation.

Altogether these results suggest that IL-18 secreted by cancer cells could enhance IFNγ production by TCR-activated γδ T cells. We tested this hypothesis using anti-IL-18 blocking Ab (Fig. 4C). By using various Vδ2β2+ γδ T-cell clones and polyclonal cell lines as indicated, we observed that the anti-IL-18 blocking Ab, but not a control anti-IL-10 Ab, significantly decreased the effect of U373MG CS on γδ T-cell IFNγ production by almost 50% at high anti-CD3 stimulation. In the same manner than for cancer cell-derived CS, CS isolated from HCMV-infected HUVEC cells was able to enhance IFNγ secretion in the presence of anti-CD3 stimulation, in contrast to CS obtained from non-infected endothelial cells. This response was also decreased by almost 50% after using the anti-IL-18 blocking Ab (irrespective to anti-IL10).

To confirm these results in a more physiological setting of TCR stimulation, which involves the γδ TCR-dependent recognition of stress antigens expressed by target cells, we used our model of γδ T-cell activation by cancer cells or HCMV-infected cells.35 We tested whether target cell-release of IL-18 was also involved in γδ T-cell activation. U373MG and γδ T-cell

Figure 2 (see previous page). IL-18 alone enhances IFNγ production by purified Vδ2β2+ γδ T cells in a TCR-dependent manner. Human Vδ2β2+ γδ T-cell clones including (A) Vγ4Vδ5 or (B) Vγ8Vδ3 purified from human PBMCs were cultured through polyclonal activation and incubated with various concentrations of anti-CD3 in the presence or absence of IL-18 or IL-1β for 24 h at 37°C; then, IFNγ secretion was measured by ELISA from cell culture supernatants (mean ± SD; n = 3). The same procedure was applied to purified Vδ2β2+ γδ T polyclonal cell lines isolated from kidney transplant patients, including (C) Vδ1+Vδ3, or (D) Vδ1, or (E) Vδ5 γδ T cells. Polyclonal cell lines were incubated with various concentrations of γδ TCR agonists (anti-Vδ1, or anti-Vδ3, or anti-CD3 antibodies) in the presence or absence of either IL-18 or IL-1β for 24 h at 37°C. Anti-CD57 was used as negative control for TCR stimulation. IFNγ secretion was then measured by ELISA from cell culture supernatants (mean ± SD; n = 3). (F) Vδ2 γδ T-cell polyclonal cell lines were isolated from PBMCs of 2 healthy donors and cultured through polyclonal activation using 4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) and IL-2, then incubated with various concentrations of γδ TCR agonist anti-Vδ2 in the presence or absence of either IL-18 or IL-1β for 24 h at 37°C. Anti-CD57 was used as negative control for TCR stimulation. IFNγ secretion was then measured by ELISA from cell culture supernatants (mean ± SD; n = 3). (G) A Vδ1 γδ T polyclonal cell line was treated with anti-CD3 in the presence or absence of various cytokines alone or in combination for 24 h at 37°C. IFNγ secretion was then measured by ELISA from cell culture supernatants (mean ± SD; n = 3). (H) A Vδ1 γδ T polyclonal cell line treated with anti-CD3 and cell culture supernatant was used to monitor IFNγ, IL-18, or IL-12 secretion by ELISA. LPS/ATP-treated THP-1 cells were used as positive control for cytokine secretion (mean ± SD; n = 3). (I) The various Vδ2β2+ γδ T-cell clone and polyclonal cell line responses to IL-18 are represented as fold induction of IFNγ secretion by IL-18 (IL-18 + TCR agonist/TCR agonist).
Figure 3. γδ TCR signaling increases membrane IL-18Rβ chain expression. (A) A Vδ1 γδ T polyclonal cell line, Vγ9Vδ1 cell clone, or B-cell lymphoma BEBV cell line were incubated with various concentrations of anti-CD3 for 24 h at 37°C, and immunostained with PE-conjugated anti-IL-18Rβ or IgG-PE control (for the Vδ1 γδ T polyclonal cell line). The expression of membrane IL-18Rβ chain was determined by flow cytometry within the healthy cell population. IL-18Rβ-PE⁺ cells are shown in the gate with the percentage of positive cells as indicated. (B) Bar graph summarizing IL-18Rβ-PE⁺ cells (%) from various Vδ2neg γδ T-cell clones (Vγ9Vδ1) and polyclonal cell lines (Vδ1, Vδ1+Vδ3, Vδ5) after incubation with various concentrations of anti-CD3. Data are representative of at least 3 independent experiments with similar results (mean of at least 5×10⁶ cells).
co-culture induced a robust IFN\(\gamma\) secretion that was further inhibited by increasing concentrations of neutralizing anti-IL-18 monoclonal antibody (mAb; in contrast to control anti-IL-10) (Fig. 5A). Moreover, anti-IL-18 mAb also inhibited cytotoxic functions of the \(\gamma\delta\) T-cell clone as measured by expression of CD107a using flow cytometry (Fig. S3). In addition, HUVEC and \(\gamma\delta\) T-cell co-culture also induced IFN\(\gamma\) secretion but only when endothelial cells were infected by HCMV. Moreover, co-culture in the presence of anti-IL-18 partially but specifically blocked IFN\(\gamma\) secretion, as shown with anti-IL-10 negative control. Therefore, CS and co-culture experiments confirmed that tumor and infected–cell-derived IL-18 enhances \(\gamma\delta\) T-cell IFN\(\gamma\) production and cytotoxic function.

**IL-18 secretion from tumor and infected target cells depends on caspase-1 activation**

The inactive pro-IL-18 precursor must be cleaved through caspase-1-dependent processing to generate an active cytokine that is secreted to prime the adaptive immune response. Prior to this, procaspase-1 itself needs to be activated by proteolytic cleavage upon assembly of NLR inflammasomes. However, in some circumstances including Fas signaling, IL-18 and IL-1\(\beta\) can be processed by a non-canonical caspase–8-dependent process. To gain insights into the mechanism of IL-18 maturation in cancer cells and HCMV-infected cells, we evaluated caspase-1 cleavage in these cells by Western blotting. THP-1 monocytic cells activated by LPS/ATP (described to induce caspase-1 processing) were used as positive controls to detect protein sizes of procaspase-1 and active cleaved forms of caspase-1 (p45 and p10, respectively). We detected a basal expression of p45 in human cancer cell lines including glioblastoma U373MG, U251, U343MG, and lung SKMES-1 (Fig. 6A). Interestingly, all cancer cell lines tested expressed the ultimate p10 active cleaved fragment, in contrast to...
the non-transformed MRC5 lung cell line used as a negative control. Therefore, processed and active caspase-1 is expressed to various extents in all cancer cell lines. In Figure 6B, we observed that human endothelial cells also express the inactive form p45 that is further cleaved in HCMV-infected cells into the detectable p35 cleaved form. Cell lysates were incubated with a Biotinyl-conjugated peptide that binds specifically to the active catalytic site of caspase-1 (Biotin-YVAD-fmk), and the active p10 fragment could only be precipitated from HCMV-infected HUVECs lysates. Therefore, caspase-1 is expressed and cleaved in both types of tissue-derived target cells of Vβ2<sup>neg</sup> γδ T cells (cancer cells and HCMV-infected cells).

Because secreted IL-18 from target cells induced IFNγ production by Vβ2<sup>neg</sup> γδ T cells and caspase-1 was expressed and cleaved in target cells, we tested whether inhibition of active caspase-1 might impair IL-18 secretion and, therefore, Vβ2<sup>neg</sup> γδ T-cell responsiveness. In Fig. 6C (left), we prepared conditioned cell CS of U373MG cancer cells cultured in the absence or presence of a specific caspase-1 pharmacological inhibitor (Ac-YVAD-fmk), and subsequently tested the IFNγ response of a polyclonal Vδ1 γδ T-cell line to YVAD-treated CS. The addition of Ac-YVAD-fmk to U373MG cancer cells strongly decreased the ability of YVAD-treated CS to induce IFNγ production (>50%), even at the lowest concentration tested (11 μmol/L). Both 11 and 33 μmol/L Ac-YVAD-fmk concentrations did not induce cytotoxicity of U373MG cancer cells (data not shown). Moreover, treatment of Vδ1 cells with Ac-YVAD-fmk in fresh media did not impair IFNγ secretion (Fig. 6C, right). Similar results were obtained when using HCMV-infected cells instead of cancer cells (Fig. 6D). We then tested the effect of caspase-1 inhibition by Ac-YVAD-fmk on U373MG cancer cells directly co-cultured with Vδ5 γδ T cells (Fig. 6E). Consistent with results obtained using CS, the use of Ac-YVAD-fmk inhibited IFNγ secretion at least as efficiently as neutralizing anti-IL-18 mAb. As a control, Ac-YVAD-fmk did not inhibit the anti-CD3-induced IFNγ production by Vδ5 γδ T cells and, thus, had no direct effect on γδ T-cell activation. Therefore, caspase-1 activity in both target cells (cancer and CMV-infected cells) regulates the secretion of soluble molecules that trigger IFNγ production by γδ T cells, following TCR signaling. Caspase-1 inhibition as well as IL-18 blocking experiments resulted in a reproducible 50% reduction of IFNγ production, which suggest that other caspase-1-independent soluble molecules besides IL-18 may be active on γδ T cells in these conditions.

**Discussion**

Human Vδ2<sup>neg</sup> γδ T cells combine innate and adaptive features, and although we and others have show that they display a
Figure 6. For figure legend, see next page.
dual reactivity against tumor and CMV-infected cells, the mechanisms by which they participate in lymphoid stress surveillance are poorly defined. Further knowledge of the mechanisms underpinning their stress surveillance function has clear relevance for the control of malignancy and virus infection in humans. Here, we report a molecular link that orchestrates the adaptive and the innate arm of γδ T cells through the γδ TCR-dependent sensing of soluble inflammatory molecules. Specifically, γδ TCR stimulation modulates the sensitivity to the inflammatory cytokine IL-18, whose production is controlled by activation of caspase-1 inflammasomes in stressed non-myeloid human cells (malignant cells and HCMV-infected cells). γδ T-cell sensitivity to IL-18 is controlled by the expression level of the innate membrane receptor IL-18Rβ. The combination of γδ TCR and IL-18R signaling ultimately leads to enhanced IFNγ production and cytotoxicity. Importantly, tissue-derived and soluble IL-18 seems sufficient to enhance γδ T-cell effector functions as no other co-factor expressed by APCs, such as IL-12, are required.

Altogether, our data suggest that, in addition to the γδ TCR recognition of specific stress antigens expressed by tumor and infected cells, epithelial Vδ2pos γδ T cells fine tune their effector functions by directly sensing cues in the form of soluble molecules including innate cytokines. This observation illustrates an intricate array of molecular events involved in the lymphoid stress surveillance mediated by the immune system, which may explain the complex stress signature recognized by some Vδ2pos γδ T-cell clones. This array of events comprises both innate-like components (innate cytokine receptor-mediated and perhaps others) and adaptive components (TCR-specific).

The low diversity of γδ TCRs is hypothesized to allow responses to a wide range of stress antigens. The TCR-dependent innate sensing mechanism we report herein would add an extra level of safety control whether to engage in potent cytotoxicity and, therefore, potentially irreversible destruction of epithelial structures, only when disturbed epithelial cells display a complex membrane stress signature. This could include stress antigens, inflammatory signals, and co-stimulating/inhibitory receptors and adhesion molecules (NKG2D, KIRs, CD100, JAML, etc.) that are all necessary to fine tune the γδ T-cell-mediated immune outcome. In the context of tissue homeostasis, such mechanisms may restrain autoinflammation, as disturbed epithelial cells releasing all signals including inflammatory cytokines would be rapidly eliminated, thereby avoiding harmful activation of myeloid cells.

We show here that secreted inflammatory soluble molecules can originate directly from stressed epithelia or endothelium, and not only from APCs. Engagement of the γδ TCR orchestrates the expression level of innate immune sensors deployed to fine tune a stress-level appropriate response. Therefore, Vδ2pos γδ T cells may act as autonomous sentinels of epithelial structures by answering back promptly to tissue threats without needing other immune cells including APCs. Activation of caspase-1 inflammasomes in target cells becomes pivotal for the secretion of innate soluble molecules. Active caspase-1 holds several functions beyond its seminal cytokine regulation. Therefore, we can also consider a putative role in regulating the expression of γδ TCR stress ligands (for e.g., through post-translational modifications).

Peripheral Vγ9Vδ2 γδ T cells sense inflammatory cytokines (IL-1β) produced by caspase-1 inflammasomes in APCs, and trigger a Th17 response in the presence of IL-23. However, sensing of innate cytokines has not yet been demonstrated for epithelial Vδ2pos γδ T cells, nor has the relationship between cytokine sensing and γδ TCR signaling in the context of epithelial immunosurveillance. We found that IL-18 is secreted by various cancer cell lines (unlike IL-1β) and by HCMV-infected endothelial HUVEC cells. It has been shown previously that murine CMV infection triggers the AIM2 inflammasome in mouse macrophages followed by caspase-1 activation and the subsequent maturation and secretion of IL-18. In turn, IL-18 mediates IFNγ production by NK cells in vivo that conveys protection to infected mice. Similarly, we show here that HCMV triggers caspase-1 activation in non-immune human endothelial cells to secrete mature IL-18, which in turn enhances IFNγ production by Vδ2pos γδ T cells. Such observations provide new perspectives related to the intrinsic response of human cells to HCMV infection, and raise the question of which inflammasome(s) is responsible for IL-18 production by infected cells.

Interleukin-18 has a contrasting role in cancer in vivo, being either protective at early stage or pro-tumoral at later stages of disease progression. Interestingly, various epithelial cells express NLRs that assemble into inflammasome complexes to activate caspase-1. In turn, active caspase-1 in colon epithelial cells...
proteins alone, although their sensitivity would be provided by a combination of both cytokines slightly increases IFNγ production and cytotoxicity due to the fact that NK cells constitutively express high amounts of cytokine membrane receptors (IL-18R and IL-12R2). In contrast, αβ T cells have been reported to require a combination of both cytokines IL-18 and IL-12 to synergistically induce IFNγ production in the presence or absence of TCR engagement. This synergism is mediated by the induction of IL-18R on naive T cells following IL-12 signaling, and by subsequent regulation of IL-12Rβ2 by IL-18. Importantly, naive T cells from IL-12−/− mice fail to produce IFNγ when stimulated with anti-CD3 and IL-18, although we cannot exclude a IL-18 response in the absence of IL-12 in other settings with differentially activated αβ T cells. Therefore, our results suggest that γδ T cells may display an alternative scenario regarding the regulation of IFNγ production by innate cytokines: like NK cells, γδ T cells do not need APC products (IL-12, IL-15) in the presence of IL-18, although they do require an additional signal for being sensitized that is provided by a γδ TCR-dependent upregulation of the IL-18 receptor. Together, γδ T cells join NK cells for their capacity to sense tissue-derived molecules alone, although their sensitivity would be more finely tuned by γδ TCR engagement. Because IL-12Rβ2 signals through JAK2/TYK2-dependent activation of STAT4 to upregulate gene expression of IL-18Rβ in αβ T cells, it is tempting to speculate that the γδ TCR has evolved to connect to the same JAK2/TYK2 signaling pathway, thereby sensitizing γδ T cells to tissue-derived soluble triggers. This putative difference between γδ and αβ T cells regarding the IL-18 response mechanism is intriguing and deserves further investigation.

Of note, the γδ TCR sensitizes not only to soluble IL-18 but also to other unknown soluble molecules that originate from disturbed tissue-derived cells. Additional soluble triggers of γδ T cells might be metabolites that originate from dysregulated metabolic pathways, as disturbed target cells undergo major and similar metabolic changes during carcinogenesis and CMV infection that are consistent with inflammasome activation. Such small molecules may constitute new DAMPs, and their identification as well as their innate sensor machineries (presumably pattern recognition receptors) would constitute attractive tools to promote first-line γδ T-cell-mediated antitumor or anti-infectious immune responses. Such knowledge may, therefore, offer new clinical strategies of anticancer-or anti-infectious immunotherapy.

Materials and Methods

Human γδ T cell clone and line generation and functional assays

Peripheral blood mononuclear cells were generated from blood samples collected for medical care with the approval of the local medical ethics committee. Primary γδ T-cell lines (Vβ1, Vβ1+3, Vβ3) and Vβ2neg γδ T-cell clones (Vγ8Vβ3, Vγ2Vβ3) were generated and cultured following the same methods as described previously. For co-culture functional assays and IFNγ secretion, primary T-cell lines and clones (5 × 10⁴ cells per well) were incubated with monolayers of tumor cell lines or HUVECs that were uninfected or infected with the human CMV clinical strain TB40-E as described. After 24 h at 37°C, supernatants were isolated by centrifugation, and cytokine secretion (IFNγ and TNFα) was measured by ELISA. Alternatively, primary γδ T-cell lines and clones (5 × 10⁴ cells per well) were left untreated or treated with recombinant cytokines IL-18/IL-1β/IL-15 (50 ng/mL) or IL-12 (20 ng/mL). From co-culture experiments, the degranulation potential of γδ T cells was analyzed by measuring the expression of CD107a. Cells were co-cultured for 6 h in the presence of PE-conjugated mAb to CD107a (H4A3; BD Biosciences) and brefeldin A (10 μg/mL) and then collected and stained with phycoerythrin–indodicarbocyanine-neg-conjugated mAb to γδ TCR (IMMU510; Beckman Coulter); then, the expression of CD107a on γδ TCR+ cells was analyzed by flow cytometry. In some experiments, anti-IL-18 or anti-IL-10 Abs were added to culture media at various concentrations. Alternatively, conditioned culture supernatants from tumor cell lines and HUVECs uninfected or infected with HCMV obtained after 48 h were isolated by centrifugation and kept frozen at −80°C. Then, primary γδ T-cell lines and clones (5 × 10⁴ cells per well) were incubated with immobilized anti-CD3 (OKT3 clone) in a 96-well plate. The plate was then centrifuged (2,500 rpm, 1 min) and media was replaced by conditioned culture supernatants for 24 h at 37°C. γδ T cells in the 96-well plate were then pelleted by centrifugation (2,500 rpm, 1 min) and the supernatant was used to measure cytokine secretion by ELISA.

Immunoblotting and recovery of active caspase-1

Immunoblotting was carried out as described previously. For recovery of active caspase-1, pellets of HUVECs uninfected or infected with HCMV were suspended in IP buffer (50 mmol/L Tris–HCl, pH 7.4, 150 mmol/L NaCl, 50 mmol/L NaF,
0.3% NP-40, 0.1 mmol/L Na3VO4), 20 μg/mL leupeptin, 20 μg/mL aprotinin, 1 mmol/L phenylmethyl sulfonyl fluoride (PMSF)). After centrifugation at 16,500 rpm/20 min at 4°C, cleared lysates were incubated with biotinylated-Fdnm (30 μmol/L) for 30 min at 37°C to precipitate the active cleaved fragment p10 of caspase-1. The biotinylated-Fdnm/caspase-1 p10 complex was recovered by using streptavidin-Sepharose beads (SIGMA), adding 30 μL of the 1:1 streptavidin-Sepharose suspension per 250 μL of IP buffer for 3 h at 4°C. Beads were pelleted by centrifugation (3,000 rpm/10 min at 4°C) and washed 3 times in cold IP buffer before adding an SDS loading buffer on top of the beads. Beads were then heated for 5 min, pelleted, and the supernatant was analyzed by SDS-PAGE/immunoblotting using an Ab that detects the p10 small subunit of processed human caspase-1 (sc515; Santa Cruz Biotechnology). For positive control of caspase-1 cleavage, THP-1 cell lines immunoblotting using an Ab that detects the p10 small subunit was recovered by using streptavidin-Sepharose beads. Beads were then heated for 5 min, pelleted, and the supernatant was analyzed by SDS-PAGE/immunoblotting using an Ab that detects the p10 small subunit of processed human caspase-1 (sc515; Santa Cruz Biotechnology). For positive control of caspase-1 cleavage, THP-1 cell lines were treated with 50 ng/mL phorbol 12-myristate 13-acetate (PMA) for 12 h at 37°C. Adherent cells were cultured with fresh media (RPMI) and then treated with 1 μg/mL LPS for 6 h, followed by 5 mmol/L ATP (for 30 min).

Reagents and Antibodies

Anti-human CD3 Ab was purchased from Biolegend (clone OKT3, 317302); anti-human Caspase-1 p10 Ab (C-20) from Santa Cruz Biotechnology (sc515); anti-human IL-18 blocking Ab from Mabtech (3420–1H-20 and 3510–1H-20; Elysis); anti-human IL-12 and mature human IL-18 from MBL. Most data were presented as the mean ± SD from at least 3 independent experiments. Statistical comparisons between different treatments were done by unpaired t-test, where P < 0.05 was considered statistically significant.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank the SFR TransBioMed flow cytometry facility.

Funding

This study was supported by the Agence Nationale de la Recherche, Fondation pour la Recherche Médicale (DEQ20110421287), INCa-Canceropole GSO, Ligue contre le Cancer de la Dordogne, and the Conseil Régional d’Aquitaine.

References

1. Chien Y, Meyer C, Bonneville M. γδ T cells: first line of defense and beyond. Ann Rev Immunol 2014; 32:1211–55; PMID:24887714; http://dx.doi.org/10.1146/annurev- immunol-032713-120216
2. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunity. Nat Rev Immunol 2013; 13:88–100; PMID:23538415; http://dx.doi.org/10.1038/nri3384
3. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glaser E, Filler R, Hobby P, Sumon B, Tigelau RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294:605–9; PMID:11567106; http://dx.doi.org/10.1126/science.1065916
4. Born W, Cady C, Jones-Caron J, Mukasa A, Lahn M, O’Brien R. Immunoregulatory functions of gamma delta T cells. Adv Immunol 1999; 71:77–144; PMID:9971911; http://dx.doi.org/10.1016/S0065-2776(08)06040-9
5. Ma Y, Aymeric L, Locher C, Mattarollo SR, Delhaye NF, Pereira P, Bouconnet L, Apetot L, Gühringhelli F, Casares N et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011; 208:491–503; PMID:21383056; http://dx.doi.org/10.1084/jem.20100269
6. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weis singer F, Rauburger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003; 102:200–6; PMID:12623838; http://dx.doi.org/10.1182/blood-2002-12-3665
7. Lafarge A, Merville P, Cazin MC, Berge F, Potaux L, Moreau JF, Déchanet-Merville J. Cytomegalovirus infection in transplant recipient resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis 2001; 184:533–41; PMID:11494158; http://dx.doi.org/10.1086/322843
8. Peng G, Wang HY, Peng W, Kiniwa Y, See KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 2007; 27:334–48; PMID:17656116; http://dx.doi.org/10.1016/j.immuni.2007.05.020
9. Brandes M, Willmann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. Science 2005; 309:264–8; PMID:15933162; http://dx.doi.org/10.1126/science.1110267
10. Touloum A, Breton L, Taylor KR, Tenenhaus J, Blav sar D, Lanigan C, Rudolph R, Jameson J, Havran WL. A role for human skin-resident T cells in wound healing. J Exp Med 2009; 206:743–50; PMID:19307328; http://dx.doi.org/10.1084/jem.20081178
11. Fisher JP, Heujiérans J, Yan M, Gautafsson K, Anders on J. γδ T cells for cancer immunotherapy: a systematic review of clinical trials. Oncoimmunology 2014; 3: e27572; PMID:24754216; http://dx.doi.org/10.4161/ onci.27572
12. Siegers GM, Lamb LS. Cytotoxic and regulatory properties of circulating Vβ1+ γδ T cells: a new player on the cell therapy field? Mol Ther J Am Soc Gene Ther 2014; 22:1416–22; http://dx.doi.org/10.1038/mct.2014.104
13. Déchanet J, Merville P, Lim A, Reière C, Pitard V, Lafarge X, Michelson S, Méric C, Hallett MM, Kourilsky P et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 1999; 103:1437–49; http://dx.doi.org/10.1172/JCI95409
14. Pitard V, Roumances D, Lafarge X, Couzi L, Garrigue I, Lafon ME, Merville P, Moreau JF, Déchanet-Merville J. Long-term expansion of effector/memory Vdelta2-gamma delta T cells is a specific blood signature of CMV infection. Blood 2008; 112:1317–24; PMID:18539896; http://dx.doi.org/10.1182/blood-2008-01-136713
15. Elh S, Schwartz K, Enders A, Duf fner U, Pannicke U, Kühn J, Mascart F, Schmitt-Gräff A, Niemeyer C, Fisch P. A variant of SCID with specific immune responses and predominance of gamma delta T cells. J Clin Invest 2005; 115:3140–8; PMID:16210194; http://dx.doi.org/10.1172/JCI25221
16. Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottari dis P, Mackinnon S, Travers PJ, Lowdell MW. The role of Vβ6-negative γδ T cells during cytomegalovirus reactiva tion in recipients of allogeneic stem cell transplantation. Blood 2010; 116:2164–72; PMID:20570814; http://dx.doi.org/10.1182/blood-2010-01-255166
17. Vermijlen D, Brouwer M, Donner C, Liesnard C, Tackoen M, Van Ryssele berghe T, Twité N, Goldman M, Marchant A, Willems F. Human cytomegalovirus elicits fetal gammadelta T cell response in utero. J Exp Med 2010; 210:807–21; PMID:20368575; http://dx.doi.org/10.1084/jem.20090348
18. Willocx CR, Pitard V, Netzer S, Couzi L, Salim M, Sil berzahn T, Moreau JF, Hayday AC, Willocx BE, Déchanet-Merville J. Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor. Nat Immunol 2012; 13:872–9; PMID:22885985; http://dx.doi.org/10.1038/ni.2394
19. Couzi L, Levallain Y, Jamai A, Pitard V, Lasalle R, Mar tin K, Garrigue I, Hawchar O, Siberchock F, Moore N,
